This Project builds upon the strengths of the Katze laboratory in genomics, proteomics, and bioinformatics to develop systems level views of the virus-host interactions and viral and host genetic determinants that regulate and determine the outcome of infection. To achieve this goal, we will work closely with investigators from the University of North Carolina (Project 3.1) and the University of Wisconsin (Project 3.2) who will be using infection models of SARS-CoV, influenza, and Ebola viruses. In addition to the extensive amount of microarray data that we will be collecting on these infection models, we will integrate proteomics, metabolomics, and lipidomics data that will also be available for selected infection models.
In Aim 1, we will use gene expression data to obtain expression quantitative trait loci (eQTL) mapping in screens of 400 genetically distinct mice, comparing the infection outcomes with SARS-CoV, influenza, and Ebola viruses.
Aim 2 generates a systems level view of viral virulence and disease progression from more detailed animal models;data integration is a key aspect to make optimal use of genomic and proteomic data for better understanding gene and protein function, as well as discerning how gene expression and protein abundance changes correlate with innate and adaptive immune responses and eventual disease outcome.
In Aim 3, we will use genomic approaches to furnish a comprehensive view of the changes in host gene expression that occur in response to the Ebola virus immunization regimens described in Project 3.2. These data may suggest genomic markers of protective immunity or indicate the predisposition of an animal to a particular response to immunization and subsequent challenge. Together, these aims provide an integrated approach that markedly enhances synergy among the collaborating projects by allowing us and our collaborators to place experimental findings in the context of a more comprehensive picture of the infection process. In addition, our high-throughput studies are likely to provide molecular signatures that predict protective immunity or pathology, candidate biomarkers for diagnostic or prognostic assays, and a rational basis for improvements to antiviral therapies or vaccine strategies.

Public Health Relevance

Treatment and vaccination options for these highly virulent viruses are either non-existent or work poorly. Our proposed studies will provide a better understanding of how the innate and adaptive immune responses recognize and fight these viruses, which will suggest new drug development and vaccination strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI081680-05
Application #
8436323
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
5
Fiscal Year
2013
Total Cost
$872,813
Indirect Cost
$150,876
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Jessica L; Stein, David A; Shum, David et al. (2014) Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. J Virol 88:5533-42
Trobaugh, Derek W; Gardner, Christina L; Sun, Chengqun et al. (2014) RNA viruses can hijack vertebrate microRNAs to suppress innate immunity. Nature 506:245-8
Haick, Anoria K; Rzepka, Joanna P; Brandon, Elizabeth et al. (2014) Neutrophils are needed for an effective immune response against pulmonary rat coronavirus infection, but also contribute to pathology. J Gen Virol 95:578-90
Gibbs, David L; Gralinski, Lisa; Baric, Ralph S et al. (2014) Multi-omic network signatures of disease. Front Genet 4:309
Gardner, Christina L; Hritz, Jozef; Sun, Chengqun et al. (2014) Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719
Josset, Laurence; Tchitchek, Nicolas; Gralinski, Lisa E et al. (2014) Annotation of long non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts. RNA Biol 11:875-90
Nikolich-┼Żugich, Janko (2014) Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol 193:2622-9
Engelmann, Flora; Josset, Laurence; Girke, Thomas et al. (2014) Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis 8:e3295
Pal, Pankaj; Fox, Julie M; Hawman, David W et al. (2014) Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88:8213-26
Fontaine, Krystal A; Camarda, Roman; Lagunoff, Michael (2014) Vaccinia virus requires glutamine but not glucose for efficient replication. J Virol 88:4366-74

Showing the most recent 10 out of 75 publications